FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2501575425> ?p ?o ?g. }

• W2501575425 abstract "The Bv8/Prokineticins (PKs) are a new family of peptides identified in frog, fish, reptiles and mammals that signal through two highly homologous G-protein coupled receptors, PKR1 and PKR2. Over the past few years, several biological functions of Bv8/PK proteins have been elucidated. The high expression level of human Bv8/PK2 in bone marrow, lymphoid organs and leukocytes suggested an involvement of these peptides in hematopoiesis and in inflammatory and immunomodulatory processes. Neutrophils are the main endogenous source of Bv8/PK2, while G-CSF is the the only cytokine able to activate PK2 expression in neutrophiles. Moreover G-CSF derived pain seems to be stronlgly related to blood levels of Bv8/PK. According to these results, we started a clinical experimental trial in order to explore role and expression of Bv8/PK proteins in patients treated with chemotherapy for early breast cancer and receiving G-CSF (filgrastim vs peg-filgrastim), investigating also the relationship with G-CSF related pain. Methods: 20 BC pts were submitted to adjuvant FEC100. G-CSF was given as primary prophylaxis. 12 pts received Lenograstim (L: 5 doses, beginning 96 hours after CT) while 8 pts received Pegfilgrastim (P: 1 dose 24 hours after CT). Real-Time PCR and Elisa test were used to analyze Bv8/PK2 expression both in pts receiving L and P. Blood samples for Bv8/PK2 analysis were taken in different steps and days, in order to evaluate Bv8/PK2 expression according to CT time and G-CSF administration. Incidence of neutropenia (N), febrile-N and BP (NRS) were evaluated in all CT cycles. 6 healthy women were recruited as controls to evaluate their Bv8/PK2 basal level. Results: An impressive increase of Bv8/PK2 expression was observed both in L and P group. N occurred in 41.6% of pts treated with L (G3: 8.3%; G4: 16.7%) and in 75% of pts with P (G3: 12.5%; G4: 62.5%; 1 FN). In pts receiving L an incidence of BP occurred in 59.3% (NRS 7-8: 41%) with a mean duration of 6 days; in P group incidence was 37.5% (NRS 7-8: 37.5%), BP lasting 4 days. In all pts BP started within 24-48 hours after G-CSF administration, concurrently with Bv8/PK2 overexpression. Conclusions: Our preliminary results suggest an emerging role of Bv8/prokineticin system in occurrence of G-CSF related BP in primary prevention of CT induced N. Therefore, inhibition of Bv8/PK2 activity should constitute a promising therapeutic strategy to prevent inflammatory pain and perhaps other cancer characteristics. Citation Format: Luigi Rossi, Anselmo Papa, Federica Tomao, Lucia Negri, Silverio Tomao. Relationship of G-CSF related bone pain (BP) with Bv8/PK2 expression in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1437." @default.
• W2501575425 created "2016-08-23" @default.
• W2501575425 creator A5011813426 @default.
• W2501575425 creator A5016900705 @default.
• W2501575425 creator A5051791738 @default.
• W2501575425 creator A5058082424 @default.
• W2501575425 creator A5072059804 @default.
• W2501575425 date "2016-07-15" @default.
• W2501575425 modified "2023-09-27" @default.
• W2501575425 title "Abstract 1437: Relationship of G-CSF related bone pain (BP) with Bv8/PK2 expression in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)" @default.
• W2501575425 doi "https://doi.org/10.1158/1538-7445.am2016-1437" @default.
• W2501575425 hasPublicationYear "2016" @default.
• W2501575425 type Work @default.
• W2501575425 sameAs 2501575425 @default.
• W2501575425 citedByCount "0" @default.
• W2501575425 crossrefType "proceedings-article" @default.
• W2501575425 hasAuthorship W2501575425A5011813426 @default.
• W2501575425 hasAuthorship W2501575425A5016900705 @default.
• W2501575425 hasAuthorship W2501575425A5051791738 @default.
• W2501575425 hasAuthorship W2501575425A5058082424 @default.
• W2501575425 hasAuthorship W2501575425A5072059804 @default.
• W2501575425 hasConcept C121608353 @default.
• W2501575425 hasConcept C126322002 @default.
• W2501575425 hasConcept C143998085 @default.
• W2501575425 hasConcept C2776139714 @default.
• W2501575425 hasConcept C2776694085 @default.
• W2501575425 hasConcept C2777063308 @default.
• W2501575425 hasConcept C2778658803 @default.
• W2501575425 hasConcept C2778850193 @default.
• W2501575425 hasConcept C2779171977 @default.
• W2501575425 hasConcept C2780007613 @default.
• W2501575425 hasConcept C530470458 @default.
• W2501575425 hasConcept C71924100 @default.
• W2501575425 hasConcept C90924648 @default.
• W2501575425 hasConceptScore W2501575425C121608353 @default.
• W2501575425 hasConceptScore W2501575425C126322002 @default.
• W2501575425 hasConceptScore W2501575425C143998085 @default.
• W2501575425 hasConceptScore W2501575425C2776139714 @default.
• W2501575425 hasConceptScore W2501575425C2776694085 @default.
• W2501575425 hasConceptScore W2501575425C2777063308 @default.
• W2501575425 hasConceptScore W2501575425C2778658803 @default.
• W2501575425 hasConceptScore W2501575425C2778850193 @default.
• W2501575425 hasConceptScore W2501575425C2779171977 @default.
• W2501575425 hasConceptScore W2501575425C2780007613 @default.
• W2501575425 hasConceptScore W2501575425C530470458 @default.
• W2501575425 hasConceptScore W2501575425C71924100 @default.
• W2501575425 hasConceptScore W2501575425C90924648 @default.
• W2501575425 hasLocation W25015754251 @default.
• W2501575425 hasOpenAccess W2501575425 @default.
• W2501575425 hasPrimaryLocation W25015754251 @default.
• W2501575425 hasRelatedWork W1968337139 @default.
• W2501575425 hasRelatedWork W2008922942 @default.
• W2501575425 hasRelatedWork W2012847675 @default.
• W2501575425 hasRelatedWork W2051052135 @default.
• W2501575425 hasRelatedWork W2142765738 @default.
• W2501575425 hasRelatedWork W2155091255 @default.
• W2501575425 hasRelatedWork W2399005340 @default.
• W2501575425 hasRelatedWork W2424249734 @default.
• W2501575425 hasRelatedWork W2483562035 @default.
• W2501575425 hasRelatedWork W2484223319 @default.
• W2501575425 hasRelatedWork W2546806369 @default.
• W2501575425 hasRelatedWork W2740542282 @default.
• W2501575425 hasRelatedWork W2906984447 @default.
• W2501575425 hasRelatedWork W2980162803 @default.
• W2501575425 hasRelatedWork W2980997319 @default.
• W2501575425 hasRelatedWork W2982901188 @default.
• W2501575425 hasRelatedWork W3002303043 @default.
• W2501575425 hasRelatedWork W3082629256 @default.
• W2501575425 hasRelatedWork W3178719583 @default.
• W2501575425 hasRelatedWork W3211846620 @default.
• W2501575425 isParatext "false" @default.
• W2501575425 isRetracted "false" @default.
• W2501575425 magId "2501575425" @default.
• W2501575425 workType "article" @default.